Expanded Use of Glivec Approved by EU: Novartis

The European Union will allow an expanded use of the drug Glivec to treat certain rare forms of gastrointestinal cancer, Novartis has revealed.

The European Commission approved an update to the Glivec label to include 36 months of treatment after surgery "for adults with KIT (CD117)-positive gastrointestinal stromal tumors (GIST)," Novartis said in a statement.

About Leukemia
Encyclopedia section of medindia gives general information about Leukemia

"Gastrointestinal stromal tumors are a rare, life-threatening cancer of the gastrointestinal tract," it said.

They are often difficult to diagnose and treat because they may not cause physical symptoms.

The cancers are usually diagnosed in patients aged between 55 and 65, and are characterised by tumors of connective tissue supporting the digestive tract.

Acute Lymphoblastic Leukemia - Incidence Causes Symptoms Diagnosis Treatment Prognosis
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lymphoblasts. It is the most common of all childhood cancers and can be fatal in weeks if left untreated.

Last year Novartis said sales of Glivec reached $4.7 billion (3.5 billion euros).

Source-AFP

Acute Myeloid Leukemia-Causes-Symptoms-Diagnosis-Treatment-Prognosis-FAQs
Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving leukemia that affects both children and adults alike

Chronic Myeloid Leukemia
Chronic myeloid Leukemia is one of the most common types of blood cancer. It is characterized by excess of WBC stem cells in the bone marrow.

MEDINDIA

Search Medindia

Expanded Use of Glivec Approved by EU: Novartis

The European Union will allow an expanded use of the drug Glivec to treat certain rare forms of gastrointestinal cancer, Novartis has revealed.